Idenix Pharma (IDIX) Receives Clinical Hold from U.S. FDA for IDX184 and IDX320 Programs
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) receives notice from the U.S. FDA that a clinical hold has been placed on IDX184 and IDX320 programs.
A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation.
The hold was put on after Idenix notified the FDA of three serious adverse events that occurred during a drug-drug interaction study of the combination of IDX184 and IDX320 in healthy volunteers.
Click here for more color from the release.
Are you missing key trading opportunities? Upgrade to StreetInsider Premium and get a step ahead of the market - FREE TRIAL!
Create E-mail AlertRelated Categories
Corporate NewsFDA
Stocks Mentioned
-0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
